{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:13:45Z","timestamp":1788398025643,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"DOI":"10.1007\/s11095-026-04178-1","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:25:05Z","timestamp":1788395105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Orthogonal Framework for Higher-Order Structural and In Vitro Functional Comparability of Chemically Synthesized Liraglutide Relative to an rDNA-Origin Reference Product"],"prefix":"10.1007","author":[{"given":"Yangming","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1049-9284","authenticated-orcid":false,"given":"Mengmeng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"6","key":"4178_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","volume":"55","author":"LV Jacobsen","year":"2016","unstructured":"Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55(6):657\u201372.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"4178_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","volume":"43","author":"LB Knudsen","year":"2000","unstructured":"Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664\u20139.","journal-title":"J Med Chem"},{"issue":"13","key":"4178_CR3","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1074\/jbc.M117.815274","volume":"293","author":"A Gajahi Soudahome","year":"2018","unstructured":"Gajahi Soudahome A, Catan A, Giraud P, Assouan Kouao S, Guerin-Dubourg A, Debussche X, et al. Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide. J Biol Chem. 2018;293(13):4778\u201391.","journal-title":"J Biol Chem"},{"issue":"9","key":"4178_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1592\/phco.31.9.896","volume":"31","author":"EM Sisson","year":"2011","unstructured":"Sisson EM. Liraglutide: clinical pharmacology and considerations for therapy. Pharmacotherapy. 2011;31(9):896\u2013911.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"4178_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","volume":"45","author":"H Agerso","year":"2002","unstructured":"Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45(2):195\u2013202.","journal-title":"Diabetologia"},{"issue":"4","key":"4178_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"4178_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med."},{"issue":"11","key":"4178_CR8","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/j.clinthera.2009.11.034","volume":"31","author":"E Montanya","year":"2009","unstructured":"Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009;31(11):2472\u201388.","journal-title":"Clin Ther"},{"key":"4178_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4178_CR10","unstructured":"EMA. Concept paper on the establishment of a guideline on the development and manufacture of synthetic peptides. In: Party QW, editor. 2022."},{"issue":"5","key":"4178_CR11","doi-asserted-by":"publisher","first-page":"8674","DOI":"10.1021\/acsomega.9b00974","volume":"4","author":"D Carbajo","year":"2019","unstructured":"Carbajo D, El-Faham A, Royo M, Albericio F. Optimized stepwise synthesis of the API liraglutide using BAL resin and pseudoprolines. ACS Omega. 2019;4(5):8674\u201380.","journal-title":"ACS Omega"},{"key":"4178_CR12","first-page":"211","volume":"3","author":"A Gross","year":"2015","unstructured":"Gross A, Hashimoto C, Sticht H, Eichler J. Synthetic Peptides as Protein Mimics. Front Bioeng Biotechnol. 2015;3:211.","journal-title":"Front Bioeng Biotechnol"},{"key":"4178_CR13","unstructured":"FDA. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin. In: Services USDoHaH, Administration FaD, (CDER) CfDEaR, editors.; 2021."},{"issue":"10","key":"4178_CR14","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s11095-024-03771-6","volume":"41","author":"M Hach","year":"2024","unstructured":"Hach M, Engelund DK, Mysling S, Mogensen JE, Schelde O, Haselmann KF, et al. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. Pharm Res. 2024;41(10):1991\u20132014.","journal-title":"Pharm Res"},{"issue":"1","key":"4178_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1208\/s12248-024-00994-8","volume":"27","author":"JA Rogers-Crovak","year":"2024","unstructured":"Rogers-Crovak JA, Delaney EJ, Detlefsen DJ. Recommendation for Clarifying FDA Policy in Evaluating \u201cSameness\u201d of Higher Order Structure for Generic Peptide Therapeutics. AAPS J. 2024;27(1):8.","journal-title":"AAPS J"},{"key":"4178_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114566","volume":"210","author":"M Gallo","year":"2022","unstructured":"Gallo M, Vanni D, Esposito S, Alaimo N, Orvieto F, Rulli F, et al. Oligomerization, albumin binding and catabolism of therapeutic peptides in the subcutaneous compartment: an investigation on lipidated GLP-1 analogs. J Pharm Biomed Anal. 2022;210:114566.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"4178_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1021\/mp500519s","volume":"12","author":"Y Wang","year":"2015","unstructured":"Wang Y, Lomakin A, Kanai S, Alex R, Benedek GB. Transformation of oligomers of lipidated peptide induced by change in pH. Mol Pharm. 2015;12(2):411\u20139.","journal-title":"Mol Pharm"},{"issue":"6","key":"4178_CR18","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.bpj.2015.07.051","volume":"109","author":"TM Frederiksen","year":"2015","unstructured":"Frederiksen TM, Sonderby P, Ryberg LA, Harris P, Bukrinski JT, Scharff-Poulsen AM, et al. Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations. Biophys J. 2015;109(6):1202\u201313.","journal-title":"Biophys J"},{"issue":"5","key":"4178_CR19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1021\/acs.molpharmaceut.9b00106","volume":"16","author":"JR Bothe","year":"2019","unstructured":"Bothe JR, Andrews A, Smith KJ, Joyce LA, Krishnamachari Y, Kashi S. Peptide oligomerization memory effects and their impact on the physical stability of the GLP-1 agonist liraglutide. Mol Pharm. 2019;16(5):2153\u201361.","journal-title":"Mol Pharm"},{"issue":"25","key":"4178_CR20","doi-asserted-by":"publisher","first-page":"13465","DOI":"10.1021\/acs.analchem.5c01851","volume":"97","author":"ST Kuo","year":"2025","unstructured":"Kuo ST, Xi Z, Cong X, Yan X, Russell DH. Dissecting hidden liraglutide oligomerization pathways via direct mass technology, electron-capture dissociation, and molecular dynamics. Anal Chem. 2025;97(25):13465\u201373.","journal-title":"Anal Chem"},{"issue":"17","key":"4178_CR21","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.3390\/molecules27175485","volume":"27","author":"V Marassi","year":"2022","unstructured":"Marassi V, Macis M, Giordani S, Ferrazzano L, Tolomelli A, Roda B, et al. Application of Af4-multidetection to liraglutide in its formulation: preserving and representing native aggregation. Molecules. 2022;27(17):5485. https:\/\/doi.org\/10.3390\/molecules27175485.","journal-title":"Molecules."},{"key":"4178_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jpba.2014.06.012","volume":"101","author":"M D'Hondt","year":"2014","unstructured":"D\u2019Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2\u201330.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"4178_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.drudis.2018.10.002","volume":"24","author":"S Rastogi","year":"2019","unstructured":"Rastogi S, Shukla S, Kalaivani M, Singh GN. Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects. Drug Discov Today. 2019;24(1):148\u201362.","journal-title":"Drug Discov Today"},{"key":"4178_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2024.115633","volume":"694","author":"AK Kuril","year":"2024","unstructured":"Kuril AK, Saravanan K, Subbappa PK. Analytical considerations for characterization of generic peptide product: a regulatory insight. Anal Biochem. 2024;694:115633.","journal-title":"Anal Biochem"},{"issue":"14","key":"4178_CR25","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.3390\/molecules26144251","volume":"26","author":"D Wang","year":"2021","unstructured":"Wang D, Zhuo Y, Karfunkle M, Patil SM, Smith CJ, Keire DA, et al. NMR spectroscopy for protein higher order structure similarity assessment in formulated drug products. Molecules. 2021;26(14):4251. https:\/\/doi.org\/10.3390\/molecules26144251.","journal-title":"Molecules."},{"issue":"4","key":"4178_CR26","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.xphs.2020.01.002","volume":"109","author":"D Wang","year":"2020","unstructured":"Wang D, Park J, Patil SM, Smith CJ, Leazer JL Jr., Keire DA, et al. An NMR-based similarity metric for higher order structure quality assessment among U.S. marketed insulin therapeutics. J Pharm Sci. 2020;109(4):1519\u201328.","journal-title":"J Pharm Sci"},{"key":"4178_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-61779-551-0_5","volume":"849","author":"M Calero","year":"2012","unstructured":"Calero M, Gasset M. Featuring amyloids with Fourier transform infrared and circular dichroism spectroscopies. Methods Mol Biol. 2012;849:53\u201368.","journal-title":"Methods Mol Biol"},{"issue":"6","key":"4178_CR28","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/jps.23554","volume":"102","author":"N Vandesteeg","year":"2013","unstructured":"Vandesteeg N, Kilbert C. Differentiation of subvisible silicone oil droplets from irregular standard dust particles. J Pharm Sci. 2013;102(6):1696\u2013700.","journal-title":"J Pharm Sci"},{"issue":"2","key":"4178_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jps.24184","volume":"104","author":"E Krayukhina","year":"2015","unstructured":"Krayukhina E, Tsumoto K, Uchiyama S, Fukui K. Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins. J Pharm Sci. 2015;104(2):527\u201335.","journal-title":"J Pharm Sci"},{"issue":"1","key":"4178_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jsb.2004.08.002","volume":"149","author":"MR Krebs","year":"2005","unstructured":"Krebs MR, Bromley EH, Donald AM. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J Struct Biol. 2005;149(1):30\u20137.","journal-title":"J Struct Biol"},{"issue":"20","key":"4178_CR31","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1111\/j.1742-4658.2009.07307.x","volume":"276","author":"SA Hudson","year":"2009","unstructured":"Hudson SA, Ecroyd H, Kee TW, Carver JA. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J. 2009;276(20):5960\u201372.","journal-title":"FEBS J"},{"issue":"3","key":"4178_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1208\/s12249-017-0911-1","volume":"19","author":"K Chen","year":"2018","unstructured":"Chen K, Park J, Li F, Patil SM, Keire DA. Chemometric methods to quantify 1D and 2D NMR spectral differences among similar protein therapeutics. AAPS PharmSciTech. 2018;19(3):1011\u20139.","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"4178_CR33","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jmb.2019.08.009","volume":"432","author":"A Tomas","year":"2020","unstructured":"Tomas A, Jones B, Leech C. New insights into beta-cell GLP-1 receptor and cAMP signaling. J Mol Biol. 2020;432(5):1347\u201366.","journal-title":"J Mol Biol"},{"issue":"11","key":"4178_CR34","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1124\/dmd.110.034066","volume":"38","author":"M Malm-Erjefalt","year":"2010","unstructured":"Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11):1944\u201353.","journal-title":"Drug Metab Dispos"},{"key":"4178_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151967","volume":"771","author":"Y Tang","year":"2025","unstructured":"Tang Y, Tang C, Lu X, Xing X. Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide). Biochem Biophys Res Commun. 2025;771:151967.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04178-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:25:11Z","timestamp":1788395111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04178-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":35,"alternative-id":["4178"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04178-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.T., M.B., and X.L. are employees of Hybio Pharmaceutical Co., Ltd. The study concerns a liraglutide product developed by Hybio Pharmaceutical Co., Ltd. X.X. is affiliated with Tsinghua University and declares no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}